WAVEMAN · COMPANY

PFE · Pfizer Inc

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

PFE

Name: PFIZER INC (PFE) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

PFIZER INC

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0000078003

CLUSTER · 3 INSIDERSC-SUITE BUYING · 1CONGRESS · 1☆ WATCH

INSIDER NET · 180D

$2.8M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

1,315

13F, latest reported quarter

REVENUE GROWTH

-1.6%

XBRL, annual

NET MARGIN

12.4%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$2.8M over 180 days

+$2.8M over 90 days

more than 92% of Pharma & Biotech

CONGRESS

1 member bought in the last year

the lowest in Pharma & Biotech

FUNDS

1,315 funds added or opened last quarter

more than 99% of Pharma & Biotech

REVENUE

-1.6% year over year

below 60% of Pharma & Biotech

MARGIN

12.4% net margin

more than 83% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

2.8% of shares outstanding short · 4.2 days to cover · settled 2026-07-31

below 58% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

3 insiders independently bought a net $2.8M — no planned sales are queued against it.

1,315 funds added or opened positions in the latest 13F quarter, of 2,831 holders.

1 member of Congress reported buying it this year.

3 trial completion dates slipped in the last 90 days.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +23.4%

+23.4%12M

INSIDER BUYINSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

3 insiders reported buying shares.

The record shows a net $2.8M bought by insiders over 180 days, 1,315 funds added last quarter, 1 Congress member(s) bought in 12 months. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, PFIZER INC insiders bought a net $2.8M of stock across 87 Form 4 purchases and sales, with 3 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

BOURLA ALBERT

Chairman & CEO

BUY

2026-08-12

38,000.0

$1.0M

Buckley Mortimer J

Director

BUY

2026-08-05

37,632.0

$960.4K

BLAYLOCK RONALD E

Director

BUY

2026-08-05

39,231.0

$998.8K

DAMICO JENNIFER B.

SVP & Controller

SELL

2026-08-05

3,278.0

$83.3K

DAMICO JENNIFER B.

SVP & Controller

SELL

2026-06-09

2,000.0

$51.4K

87 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 82 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

529,670,433.0 sh

$12.8B

VANGUARD CAPITAL MANAGEMENT LLC

372,149,852.0 sh

$9.0B

STATE STREET CORP

307,090,897.0 sh

$7.4B

GEODE CAPITAL MANAGEMENT, LLC

135,275,782.0 sh

$3.2B

VANGUARD PORTFOLIO MANAGEMENT LLC

119,235,030.0 sh

$2.9B

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Roundhill GLP-1 & Weight Loss ETF

$3.9M POSITION · AS OF 2026-03-31

7.6%

First Trust Morningstar Dividend Leaders Index Fund

$476.6M POSITION · AS OF 2026-03-31

6.5%

VanEck Pharmaceutical ETF

$67.2M POSITION · AS OF 2026-03-31

5.2%

Invesco Pharmaceuticals ETF

$17.4M POSITION · AS OF 2026-04-30

5.2%

Franklin U.S. Dividend Booster Index ETF

$3.0M POSITION · AS OF 2026-03-31

5.1%

Huber Select Large Cap Value Fund

$25.5M POSITION · AS OF 2026-04-30

5.1%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 989 registered trials, 236 still enrolling or running — a status change here is dated weeks before the press release

307

Phase 1

43 ACTIVE

109

Phase 2

28 ACTIVE

166

Phase 3

74 ACTIVE

Phase 4

9 ACTIVE

324

Not applicable

64 ACTIVE

Multi-phase

18 ACTIVE

What changed recently

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab)

2026-09-04 · Completion moved 2026-01-12 → 2026-10-30

Phase 3

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Oth

2026-09-03 · Completion moved 2026-09-01 → 2027-03-24

PHASE1,PHASE2

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combin

2026-09-02 · Completion moved 2027-08-02 → 2027-08-31

Phase 1

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combin

2026-09-02 · Recruiting → Active Not Recruiting

Phase 1

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Lon

2026-09-02 · Recruiting → Active Not Recruiting

Phase 2

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Sol

2026-09-02 · Recruiting → Active Not Recruiting

Phase 1

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Corporate PAC

FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors

Pfizer Inc. Pac

CYCLE 2026 · $1,258K SPENT

$1.3M

FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION

Executive pay vs shareholder return · Bourla

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$27.6M

$33.7M

$9.6M

-14%

+87%

2024

$24.6M

$38.5M

$8.5M

-14%

+51%

2023

$21.6M

-$62.1M

$6.3M

-12%

+43%

2022

$33.0M

$5.7M

$14.8M

+49%

+33%

2021

$24.4M

$115.2M

$9.3M

+67%

+23%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$62.6B	$63.6B	$59.6B	$101.2B
NET INCOME	$7.8B	$8.0B	$2.1B	$31.4B
EPS (DILUTED)	1.36	1.41	0.37	5.47
OPERATING CASH FLOW	$11.7B	$12.7B	$8.7B	$29.3B
CASH	$1.1B	$1.0B	$2.9B	$416.0M
LONG-TERM DEBT	$61.6B	$57.4B	$61.5B	$32.9B
BUYBACKS	—	$0	$0	$2.0B

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE